首页> 外文OA文献 >Development of an All-in-One Lentiviral Vector System Based on the Original TetR for the Easy Generation of Tet-ON Cell Lines
【2h】

Development of an All-in-One Lentiviral Vector System Based on the Original TetR for the Easy Generation of Tet-ON Cell Lines

机译:基于原始TetR的多合一慢病毒载体系统的开发,可轻松生成Tet-ON细胞系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lentiviral vectors (LVs) are considered one of the most promising vehicles to efficiently deliver genetic information for basic research and gene therapy approaches. Combining LVs with drug-inducible expression systems should allow tight control of transgene expression with minimal side effect on relevant target cells. A new doxycycline-regulated system based on the original TetR repressor was developed in 1998 as an alternative to the TetR-VP16 chimeras (tTA and rtTA) to avoid secondary effects due to the expression of transactivator domains. However, previously described TetR-based systems required cell cloning and/or antibiotic selection of tetracycline-responsive cells in order to achieve good regulation. In the present manuscript we have constructed a dual Tet-ON system based on two lentiviral vectors, one expressing the TetR through the spleen focus forming virus (SFFV) promoter (STetR) and a second expressing eGFP through the regulatable CMV-TetO promoter (CTetOE). Using these vectors we have demonstrated that the TetR repressor, contrary to the reverse transactivator (rtTA), can be expressed in excess to bind and modulate a high number of TetO operons. We have also showed that this dual vector system can generate regulatable bulk cell lines (expressing high levels of TetR) that are able to modulate transgene expression either by varying doxycycline concentration and/or by varying the amount of CTetOE vector genomes per cell. Based on these results we have developed a new all-in-one lentiviral vector (CEST) driving the expression of TetR through the SFFV promoter and the expression of eGFP through the doxycycline-responsive CMV-TetO operon. This vector efficiently produced Tet-ON regulatable immortalized (293T) and primary (human mesenchymal stem cells and human primary fibroblasts) cells. Bulk doxycycline-responsive cell lines express high levels of the transgene with low amount of doxycycline and are phenotypically indistinct from its parental cells.
机译:慢病毒载体(LVs)被认为是最有前途的载体,可以有效地为基础研究和基因治疗方法提供遗传信息。 LVs与药物诱导表达系统的结合应允许转基因表达的严格控制,对相关靶细胞的副作用最小。 1998年开发了基于原始TetR阻遏物的新的强力霉素调节系统,作为TetR-VP16嵌合体(tTA和rtTA)的替代品,以避免由于反式激活域的表达而产生的次级影响。然而,先前描述的基于TetR的系统需要细胞克隆和/或四环素反应性细胞的抗生素选择,以实现良好的调控。在本手稿中,我们基于两个慢病毒载体构建了一个双重Tet-ON系统,一个通过脾脏形成病毒(SFFV)启动子(STetR)表达TetR,另一个通过可调节CMV-TetO启动子(CTetOE)表达eGFP。 )。使用这些载体,我们已经证明,与反向反式激活子(rtTA)相反,TetR阻遏物可以过量表达以结合和调节大量TetO操纵子。我们还表明,这种双载体系统可以产生可调节的大细胞系(表达高水平的TetR),它们可以通过改变强力霉素的浓度和/或改变每个细胞的CTetOE载体基因组的数量来调节转基因表达。基于这些结果,我们开发了一种新型的多合一慢病毒载体(CEST),它通过SFFV启动子驱动TetR的表达,并通过强力霉素反应性CMV-TetO操纵子驱动eGFP的表达。该载体有效地产生了Tet-ON可调节的永生化(293T)和原代(人间充质干细胞和人原代成纤维细胞)细胞。大量的强力霉素反应细胞系表达高水平的转基因,而强力霉素含量低,并且在表型上与亲代细胞不清楚。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号